Cargando…

Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants

BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Halloran, Charlotte, Rice, Brian, White, Ellen, Desai, Monica, Dunn, David T, McCormack, Sheena, Sullivan, Ann K., White, David, McOwan, Alan, Gafos, Mitzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913514/
https://www.ncbi.nlm.nih.gov/pubmed/31739177
http://dx.doi.org/10.1016/j.drugpo.2019.10.007
_version_ 1783479652834082816
author O'Halloran, Charlotte
Rice, Brian
White, Ellen
Desai, Monica
Dunn, David T
McCormack, Sheena
Sullivan, Ann K.
White, David
McOwan, Alan
Gafos, Mitzy
author_facet O'Halloran, Charlotte
Rice, Brian
White, Ellen
Desai, Monica
Dunn, David T
McCormack, Sheena
Sullivan, Ann K.
White, David
McOwan, Alan
Gafos, Mitzy
author_sort O'Halloran, Charlotte
collection PubMed
description BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive drugs, in the UK typically; crystal methamphetamine, gamma-hydroxybutyrate(GHB) and/or mephedrone. Chemsex drug use has been associated with increased HIV transmission risk among gay, bisexual and other men who have sex with men (GBM) and poor ART adherence among people living with HIV. This study assessed whether self-reported chemsex events affected self-reported daily PrEP adherence among PROUD study participants. METHODS: The PROUD study was an open-label, randomised controlled trial, conducted in thirteen English sexual health clinics, assessing effectiveness of Truvada(Ⓡ)-PrEP among 544 HIV-negative GBM. The study reported an 86% risk-reduction of HIV from daily PrEP. Participants were asked about chemsex engagement at follow-up visits. Monthly self-reports of missed PrEP tablets were aggregated to assess adherence between visits. Univariable and multivariable regression analyses were performed to test for associations between chemsex and reporting less than seven out of seven intended doses(<7/7ID) in the 7 days before and/or after last condomless anal intercourse(CAI). RESULTS: 1479 follow-up visit forms and 2260 monthly adherence forms from 388 participants were included in the analyses, with 38.5% visit forms reporting chemsex since last visit and 29.9% follow-up periods reporting <7/7ID. No statistically significant associations were observed between reporting <7/7ID and chemsex (aOR=1.29 [95% CI 0.90–1.87], p = 0.168). Statistically significant associations were seen between reporting <7/7ID and participants perceiving that they would miss PrEP doses during the trial, Asian ethnicity, and reporting unemployment at baseline. CONCLUSIONS: These analyses suggest PrEP remains a feasible and effective HIV prevention method for GBM engaging in chemsex, a practise which is prevalent in this group and has been associated with increased HIV transmission risk.
format Online
Article
Text
id pubmed-6913514
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69135142019-12-23 Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants O'Halloran, Charlotte Rice, Brian White, Ellen Desai, Monica Dunn, David T McCormack, Sheena Sullivan, Ann K. White, David McOwan, Alan Gafos, Mitzy Int J Drug Policy Article BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive drugs, in the UK typically; crystal methamphetamine, gamma-hydroxybutyrate(GHB) and/or mephedrone. Chemsex drug use has been associated with increased HIV transmission risk among gay, bisexual and other men who have sex with men (GBM) and poor ART adherence among people living with HIV. This study assessed whether self-reported chemsex events affected self-reported daily PrEP adherence among PROUD study participants. METHODS: The PROUD study was an open-label, randomised controlled trial, conducted in thirteen English sexual health clinics, assessing effectiveness of Truvada(Ⓡ)-PrEP among 544 HIV-negative GBM. The study reported an 86% risk-reduction of HIV from daily PrEP. Participants were asked about chemsex engagement at follow-up visits. Monthly self-reports of missed PrEP tablets were aggregated to assess adherence between visits. Univariable and multivariable regression analyses were performed to test for associations between chemsex and reporting less than seven out of seven intended doses(<7/7ID) in the 7 days before and/or after last condomless anal intercourse(CAI). RESULTS: 1479 follow-up visit forms and 2260 monthly adherence forms from 388 participants were included in the analyses, with 38.5% visit forms reporting chemsex since last visit and 29.9% follow-up periods reporting <7/7ID. No statistically significant associations were observed between reporting <7/7ID and chemsex (aOR=1.29 [95% CI 0.90–1.87], p = 0.168). Statistically significant associations were seen between reporting <7/7ID and participants perceiving that they would miss PrEP doses during the trial, Asian ethnicity, and reporting unemployment at baseline. CONCLUSIONS: These analyses suggest PrEP remains a feasible and effective HIV prevention method for GBM engaging in chemsex, a practise which is prevalent in this group and has been associated with increased HIV transmission risk. Elsevier 2019-12 /pmc/articles/PMC6913514/ /pubmed/31739177 http://dx.doi.org/10.1016/j.drugpo.2019.10.007 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
O'Halloran, Charlotte
Rice, Brian
White, Ellen
Desai, Monica
Dunn, David T
McCormack, Sheena
Sullivan, Ann K.
White, David
McOwan, Alan
Gafos, Mitzy
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
title Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
title_full Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
title_fullStr Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
title_full_unstemmed Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
title_short Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
title_sort chemsex is not a barrier to self-reported daily prep adherence among proud study participants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913514/
https://www.ncbi.nlm.nih.gov/pubmed/31739177
http://dx.doi.org/10.1016/j.drugpo.2019.10.007
work_keys_str_mv AT ohallorancharlotte chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT ricebrian chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT whiteellen chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT desaimonica chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT dunndavidt chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT mccormacksheena chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT sullivanannk chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT whitedavid chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT mcowanalan chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants
AT gafosmitzy chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants